From Yahoo Finance: 2025-06-06 16:29:00

Coherus BioSciences, Inc. (CHRS) saw its share trading at $0.77 on 30th May with a trailing P/E of 1.77. The company is making strides in oncology through a partnership with STORM Therapeutics for a novel cancer treatment approach.

The collaboration between Coherus BioSciences (CHRS) and STORM Therapeutics represents a unique approach to immuno-oncology, combining toripalimab and STC-15 in a Phase 1b/2 clinical trial. This innovative strategy could lead to a new class of cancer therapy and position CHRS as a leader in immuno-oncology innovation.

Despite recent success, Coherus BioSciences (CHRS) is facing skepticism from investors due to past financial struggles and the stock’s decline by 38% as of 30th May. However, the company’s strategic vision and foray into oncology could lead to a major reevaluation of its valuation and growth trajectory.

Coherus BioSciences, Inc. (CHRS) is not among the 30 Most Popular Stocks Among Hedge Funds, with only 10 hedge fund portfolios holding the stock at the end of the first quarter. While CHRS shows potential as an investment, some AI stocks may offer greater returns with limited downside risk. Investors are advised to explore other options for potential gains.

Read more: Coherus BioSciences, Inc. (CHRS): A Bull Case Theory